function. 13 This control is mediated by two calciotropic hormones (parathyroid hormone [PTH] and vitamin D), which are discussed below. 14 These hormones act on the gut, kidney, and bone (Fig. 2) . Although the extracellular fluid calcium (900 mg, which represents about 1% of the body's calcium) is tightly controlled, there are enormous fluxes in calcium levels that take place during calcium metabolism. The kidney filters approximately 10,000 mg of calcium per day and reabsorbs about 97% of what it filters, but about 175 mg is lost through sweat, gastrointestinal secretions, and cell sloughing. If calcium levels drop below this range, the result is hypocalcemia. 15 This loss is balanced by what is absorbed by the intestine, and in zero balance, the amount of bone resorption and deposition is equivalent (500 mg/day). Bone contains about 99% of the body's calcium and not only plays a structural role but also acts as a calcium reserve. 15 If the dietary intake of calcium is insufficient, bone is resorbed to prevent hypocalcemia. The bone reserve of calcium is large enough to support normal physiologic function for months to years. The result of bone resorption, however, can be osteoporosis, which for women is defined as bone mineral density values (BMD) more than 2.5 standard deviations below those for young adult women. Osteoporosis occurs in about 21% of Caucasian women, and osteopenia (BMD 1 to 2.5 standard deviations below those for young adult women) occurs in 38% of women aged 50 and over. 16, 17 Women over the age of 50 also have a 50% chance of having an osteoporotic fracture before they die. 10, 18 In Caucasian women, the risk of hip fracture is equal to the combined risks of developing breast, uterine, and ovarian cancer. In 1995, the estimated health-care costs of osteoporotic fracture was $13.8 billion. 19 
VITAMIN D: AN ESSENTIAL HORMONE
Vitamin D enters the circulation from the skin or diet (Fig. 3) . 20 Within several hours, it accumulates in the liver where it undergoes hydroxylation to form 25(OH)D (calcidiol). This form of vitamin D is fairly stable in the body and is, therefore, a good indicator of vitamin deficiency or toxicity. In the kidney, 25(OH)D undergoes another hydroxylation to become the biologically active hormone 1,25(OH) 2 D (calcitriol), whose major function is to maintain serum calcium and phosphorus concentrations within normal ranges, by controlling absorption in the small intestine. 21 When serum calcium levels drop below the body's needs, parathyroid hormone (PTH) increases the synthesis of 1,25(OH) 2 D, which increases the absorption of calcium Holick 6, 20 The ULs for these adults were set at 2,500 mg/day for calcium and 50 µg (2,000 IU)/day for vitamin D. According to the FNB, at intakes above the UL, the risk of adverse effects (hypercalcemia) may increase, but adverse events are unlikely unless intakes of calcium reach 4 gm per day and intakes of vitamin D exceed 250 to 1,250 µg (10,000 to 50,000 IU) per day. 3 Symptoms of hypercalcemia include constipation, thirst, and malaise and can be exacerbated by cancer and hyperparathroidism. 23 AIs and ULs for all ages are given in Dietary Reference Intakes. 3 
Threshold behavior of calcium. Below the threshold, bone gain is a linear function of intake. Above the threshold, bone gain is no longer related to intake. Bone accumulation is greatest during growth, zero at maturity, and negative during involution. During involution, there is reduced retention and a greater demand for calcium intakes, as indicated by the low slope of the line and the threshold being located further to the right. During involution, some bone loss may occur because of non-dietary reasons and this loss is exacerbated by inadequate calcium intakes. (Adapted from
Heaney
Metabolic pathways of vitamin D (adapted from

PREVENTION OF INDEX DISEASES OF VITAMIN D AND CALCIUM DEFICIENCIES IS NOT ENOUGH
The current recommended intake of vitamin D is intended to prevent the index diseases of rickets and osteomalacia, and the current recommended intake of calcium is intended to prevent the index disease of osteoporosis -just as thiamine, niacin, and iodine are intended to prevent beriberi, pellagra, and goiter. 24 Low intake levels of vitamin D and calcium have, however, far more reaching consequences. Calcium that is not absorbed in the intestine binds with food oxalate, fatty acids, and bile acids. Calcium's binding with food oxalate reduces the risk of calcium oxalate (kidney) stones. 24 This is a short-term effect. A more long-term effect is that of calcium's binding with unabsorbed fatty acids and bile acids. In the bound states, these acids cause less chronic, colon-mucosa irritation, which in time can result in cancer. As discussed below, obtaining adequate vitamin D from food is problematic. There are, however, many foods that are rich in calcium (Table 1) , and it is therefore recommended that calcium be obtained from natural food sources whenever possible, with milk and other dairy products as the primary sources of calcium. 3 (Additional information is also available at http:// www.nichd.nih.gov/milk/whycal/sources.cfm).
The 1,25(OH) 2 D that is produced in the kidneys in response to low serum calcium levels is transported to the small intestine and bone (its main target organs), where it interacts with vitamin D receptors (VDRs) to increase calcium absorption in the intestine and to release calcium from bone. The 1,25(OH) 2 D also travels to various tissues where it binds to membrane receptors or insulin-dependent diabetes), there is also upregulation of the expression of IL-1, PGE 2 , and TNF-α. 29, 30 In addition, these agents appear to be up regulated in cardiovascular disease and preterm low birthweight babies. [31] [32] [33] It has also been suggested that periodontal disease and proinflammatory cytokines are associated with diabetes mellitus, cardiovascular diseases, and preterm low birthweight babies. 22, [31] [32] [33] [34] [35] In addition, hypertension, diabetes mellitus, cardiovascular diseases, and periodontal diseases are associated with obesity and, because vitamin D and 25(OH)D are stored in adipose tissue, obese subjects have low serum levels of 25(OH)D. 22, 36 Moreover, specific vitamin D-receptor genotypes have been shown to be associated with localized aggressive periodontal disease, with oral bone loss, clinical attachment loss, and tooth loss. 37, 38 OPTIMAL SERUM LEVELS OF VITAMIN D Rickets and osteomalacia, which recommended levels of supplementation are intended to prevent, occur at serum 25(OH)D levels <12.5 nmol/l (5 ng/ml), but a number of investigators convincingly argue that serum 25(OH)D levels <80 mnol/l are deficient (Fig. 5) . 7, 22, 39 Perhaps the best argument in support of this is that people who live close to the equator or who are exposed to a lot of sunshine (sunbathers and people who work outdoors) have serum 25(OH)D levels from about 100 to 160 nmol/l, with the highest level (225 nmol/l) found in a Puerto Rican and opens calcium channels. This in turn can result in obesity and hypertension. 24 The consequences of having intake levels of vitamin D that are adequate for preventing only rickets and osteomalacia can be insidious. As recently pointed out, by increasing 25[OH]D levels from ≈50 nmol/l to ≈80 nmol/l, calcium absorption can be increased by two-thirds and osteoporotic fracture risk decreased by one-third. 24 2 D, which increases lysosomal enzyme activity and phagocytosis. 22 Infectious diseases such as acute respiratory infections and pneumonia have been found to be more prevalent in children with rickets [low levels of 25(OH)D], and vitamin D status seems to be implicated in tuberculosis. 22 Conversely, the in vitro synthesis of macrophage mRNA for interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF)-α has been shown to be inhibited by 1,25(OH) 2 D, with the implication being that threshold serum levels of 25(OH)D can result in suppression of cytokine synthesis. Because of these relationships, it has been suggested that vitamin D deficiency may play roles in rheumatoid arthritis, inflammatory bowel diseases, multiple sclerosis, and hypertension -all of whose morbidities are associated with proinflammatory cytokines. 22 In addition, proinflammatory cytokines and vitamin D have been implicated in cardiovascular diseases and diabetes mellitus. 22 
PERIODONTAL DISEASE, CYTOKINE, VITAMIN D INTERCONNECTIONS
Periodontitis can be considered an abnormal inflammatory response to periodontal flora, in which hard and soft tissues are destroyed by auto-degradative mechanisms. 26, 27 As part of this process, monocytes respond to bacteria invasion and secrete cytokines, which in turn cause lymphocytic infiltration, bone resorption, and dissolution of the extracellular matrix. Cytokines (cell proteins) regulate the body's inflammatory response by transmitting signals between cells. Cytokines such as IL-1, IL-6, and TNF-α are potent osteoclastogenic signaling agents, which result in the resorption of alveolar bone. 26, 28 IL-1 also stimulates the release of metalloproteinases (MMP), which degrade the extracellular matrix and prostaglandin E 2 (PGE 2 ), which causes vasodilation, edema, and bone resorption. In Type I diabetes (formerly called juvenile diabetes farmer. 22, 40 There has never been a report of vitamin D intoxication caused by sunlight exposure in a healthy person. The serum levels of 25(OH)D (100 to 160 nmol/l) that result from intensive sunlight exposure can, therefore, be regarded as the upper safe levels. 22 In addition, with 25(OH)D serum levels below ∼80 nmol/l, there is decreased calcium absorption and increased PTH secretion, and it is speculated that the threshold for optimal calcium absorption and minimal PTH secretion occurs at 25(OH)D levels of ∼80 to 90 nmol/l. 39
Increases in Serum Levels
OBTAINING VITAMIN D FROM ORAL SUPPLEMENTATION
Although it is possible to reach these levels with vitamin D supplementation, the doses would have to be high, as indicated in Table 2 . The changes in serum 25(OH)D levels, however, are nonlinear and vary by some inverse function of baseline serum levels. 42 In an attempt to determine the amounts of vitamin D inputs needed to achieve or maintain serum 25(OH)D levels, a study of men (mean age = 39 years) was conducted in Omaha, Nebraska, during the winter. 39 
FOOD SOURCES OF VITAMIN D
There are a few natural foods and fortified foods that contain vitamin D (Table 3 ). The levels of vitamin D, however, vary depending upon the time of year food is harvested, and levels of food fortification are highly variable, with some fortified foods containing no vitamin D. Because of this, it is exceedingly difficult to obtain adequate vitamin D requirement from food. [43] [44] [45] [46] The median intake of vitamin D from food was estimated to be 2.3 µg (90 IU)/day in older women. 47 
VITAMIN D INTOXICATION
Although vitamin D intoxication can cause hypercalcemia, in all cases of vitamin D intoxication, the levels of 25(OH) were >200 nmol/l. 22 In these cases, the vitamin D doses were ≥1,000 µg (40,000 IU)/day. There has been one case for which hypercalcemia resulted from an average vitamin D supplementation of 250 µg (10,000 IU)/day; however, this person received the vitamin D in a single dose of 7,550 µg (300,000 IU). Vitamin D intoxication has been caused by accidental excessive fortification of foods (such as milk) and excessive intakes of vitamin D. 22, 41 In arguing that the UL of 50 µg (2,000 IU)/day for vitamin D set by the FNB in 1997 should be increased, one investigator summarized his review by stating, "If there is published evidence of toxicity in adults from intake of 250 µg (10,000 IU)/day, and that is verified by the 25(OH)D concentration, I have yet to find it." 41 Other investigators have also argued that the UL is set far too low. 22, 24 Although hypersensitivity to vitamin D occurs with some conditions (most notably hyperparathyroidism), this is not a good reason for setting low intake levels for vitamin D because before the condition (hyperparathyroidism) develops, the vitamin D would be preventive in that it would lower parathyroid secretion and reduce the risk of developing parathyroid hyperplasia. 41 It has been suggested that for adults daily supplementation with vitamin D at levels of 25 and 100 µg (1,000 and 4,000 IU)/day are beneficial to health and safe, and that the FNB needs to raise AI and UL for vitamin D. 8, 22, 24, [39] [40] [41] [42] 44, 48 BEST SOURCE OF VITAMIN D The best means of obtaining vitamin D requirement is from sunshine. A person wearing a bathing suit, who receives a sub-erythemal (slight redness of the skin) dose of sunshine will produce 250 µg (10,000 IU) of vitamin D. 41, 49 It is, therefore, possible for adults to obtain their body's vitamin D requirements by exposing their hands, arms, and face to a third to a half of a suberythemal dose of sunshine two to three times per week. 49 In Boston, during the spring, summer, and fall, for a lightto medium-skin-colored person, each exposure, if obtained about noon, would require about 5 minutes of exposure time and would result in about 15 to 25 µg (600 to 1,000 IU) of vitamin D, which would be adequate for vitamin D needs. People who stay outdoors longer should apply a sunscreen (SPF ≥15).
EFFECT OF VITAMIN D AND CALCIUM SUPPLEMENTATION ON POSTCRANIAL BONE
Vitamin D and calcium supplementation counteract deficiencies, and reduce bone resorption and fracture rates. [50] [51] [52] [53] [54] Vitamin D supplementation (10 µg [400 IU/ day]) and adjusted calcium intakes of 1,000 mg/day increased vertebral bone density and total body calcium in postmenopausal women, 55 and serum vitamin D levels have been demonstrated to be directly related to femoral bone mineral densities. 56 Maximum bone gains occur after 2 years of supplementation in both the femur and lumbar spine and are maintained for at least 4 years. 57 In a 2002 review of 180 articles on calcium intake and bone status, 70 studies were "investigator-controlled," which is generally recognized as the only research design capable of establishing a causal connection between exposure and outcome. 58 Sixty-eight of the 70 studies (97%) found that calcium supplementation results in either greater gains in bone during growth, less loss of bone with age, and/or reduced fracture risk, relative to unsupplemented individuals. Of the 110 observational studies, 85 (77%) reported positive effects for calcium supplementation. These findings are in keeping with other reviews. [59] [60] [61] [62] [63] Moreover, vitamin D has its greatest effect when combined with calcium supplementation 64 and, although vitamin D supplementation alone can result in bone gain, most studies have used a combination of vitamin D and calcium. 65, 66 
EFFECT OF VITAMIN D AND CALCIUM ON TOOTH LOSS
Tooth loss was studied in a double-masked, randomized, placebo-controlled trial of the effects of calcium and vitamin D supplementation on bone loss from the hip. 67 Subjects (N = 82) who received 500 mg of calcium and 700 IU of vitamin D per day for 3 years had a 60% lower risk of tooth loss than did those who took placebos. 67 These patients were followed for an additional 2 years during which time subjects who consumed at least 1,000 mg/day of calcium also had a 60% lower risk of tooth loss than subjects who took less calcium. Although some data were collected on the periodontal disease status of the patients at the end of the study, corresponding data at baseline were not available. The major limitation of this investigation was that tooth loss was a secondary outcome in the study, and tooth counts were based on self-reports by subjects who completed the study.
EFFECT OF VITAMIN D AND CALCIUM ON RESIDUAL ALVEOLAR RIDGE RESORPTION
In a cross-sectional study, low consumptions of milk and milk products were attributed to more severe residual alveolar ridge resorption in 44 edentulous subjects who completed 14-day dietary surveys. 68 The 14 subjects who had minimal ridge resorption on panoramic radiographs had a mean intake of calcium of 933 mg/day whereas the 30 subjects who had severe resorption had a mean intake of 533 mg/day. A subsequent 1-year, randomized, double-masked, placebo-controlled clinical trial of 60 subjects who received immediate dentures was performed. 69 Subjects received either placebos or 750 mg calcium and 375 IU vitamin D per day. Bone resorption over the 1-year period was measured with panoramic radiographs. Seven-day dietary records for 13 supplemented subjects and 19 placebo subjects were used to estimate calcium consumption. Details were provided on randomization, masking, methods, and reasons for dropout. Although data were not analyzed on an intention-to-treat basis, those subjects who completed the study and received supplementation (N = 23) had 36% less bone loss than did subjects who received placebo. In a cross-sectional study of 11 healthy post-menopausal women who required complete-denture replacements, the mean dietary intake of calcium was 800 mg/day and the mean serum level of vitamin D was 18.8 ng/ml. 70 The investigators suggested that these low levels contributed to low mandibular bone densities in these subjects. In another cross-sectional study, subjects were divided into five groups, based on age and number of remaining teeth. 71 The highest percentage of subjects with calcium deficient diets was in edentulous geriatric patients. Eleven edentulous patients with severe ridge atrophy underwent comprehensive biochemical and histomorphological testing prior to ridge augmentation procedures. 72 The investigators concluded that the ridge resorption was consistent with metabolic bone loss resulting from secondary hyperparathyroidism, resulting from insufficient calcium intakes. Combining these 11 subjects with 63 other subjects (total 74), the same investigators used gonial-angle thickness as a parameter for metabolic bone loss. 73 In the subjects with the thinnest gonial angles, resorption surfaces and osteoid volume and seam thickness were consistent with low calcium intakes and hyperparathyroidism.
EFFECT OF VITAMIN D AND CALCIUM ON ALVEOLAR BONE
In a 1960 cross-sectional study, two groups of 24 subjects each were followed. 74 One group had periodontal disease and the other group did not have periodontal disease. The severe radiographic alveolar bone resorption in the subjects with periodontal disease was attributed to past histories of low calcium intakes (350 to 555 mg/day), which the investigators suggested was caused by low milk ingestion. Low intakes of milk and cheese were also attributed to low dietary calcium levels (325 mg/day) in another study in which 10 subjects with periodontal disease received 1,000 mg/day of calcium supplementation and were followed for 6 months. 75 Little detail on methods is provided in this 1972 study. The investigators reported that at the end of 6 months of treatment, gingival inflammation was improved, probing depth and tooth mobility decreased, and new bone appeared to have formed as observed radiographically. In a similar study, these same investigators followed for 6 months a cohort of 10 subjects who received 1,000 mg/day of calcium. 76 No detail is provided concerning methodology. The investigators reported decreases in gingivitis, probing depth, and tooth mobility, and increases in alveolar crest bone. These investigators also followed 90 patients for one year. 76, 77 Subjects received one of three forms of calcium (1,000 mg/day) or a placebo. No detail is provided on masking, randomization, or methodology. The investigators reported that there were increases in radiographic mandibular bone density for the subjects, who received supplemental calcium. The first study (1972) 75 in this series was repeated by two other investigators in 1984. 78 Contrary to the earlier findings, no significant differences between the calcium-supplemented group and the placebo group were determined for plaque and gingival index scores or probing depths. It was also reported that radiographs studied with a magnifying glass "failed to show any changes in marginal bone level or density." 78 No data were provided for radiographic assessments. In none of these studies does it appear that standard periodontal therapies (such as dental prophylaxes or scaling and root planing) were provided. Standard periodontal therapy was provided, however, in a double-masked placebo controlled trial of 40 subjects, who received either calcium (750 mg/day) and vitamin D (375 IU/day) or placebo. 79 Thirty-three subjects finished 1 year of treatment. Nine of 15 subjects (60%) who received supplementation had improved periodontal health, whereas only three of 18 subjects (3%) who received placebos had improved periodontal health, (P <0.01). Although radiographs were obtained, they were not analyzed. Little information is provided regarding the assessment of periodontal health, so it is difficult to interpret these results.
In an examination of data on 12,000 adults who took part in the Third National Health and Nutrition Examination Survey (NHANES III), it was found that lower dietary intake of calcium increased attachment loss in a dose-dependent fashion. 80 The investigators suggested that the increased risk of periodontal disease could be related to decreased alveolar bone density associated with inadequate calcium intake. The major limitations of the study are that it was cross-sectional and lacked exact data on calcium supplementation. Other investigators used the NHANES III data to examine the association between serum vitamin D levels and attachment loss and found an inverse relationship: the lower the levels of vitamin D the more attachment loss, with the association being independent of factors such as smoking habit and diabetes. 81 They suggested that this inverse relationship might be attributable to the anti-inflammatory effects of vitamin D. The limitations of this study are that it was cross-sectional and serum levels of vitamin D were determined at only one point. In another study, dietary surveys were conducted and alveolar crest height measurements made on 550 male subjects. 82 A subject was considered to have low alveolar bone loss if the distance from the cemento-enamel junction (CEJ) to the alveolar crest on periapical radiographs was ≤20% of the distance from the CEJ to the root tip. High bone loss was defined as having a value >20%. The number of subjects who progressed from low to high alveolar bone loss was 30% higher in subjects who consumed less than 1,000 mg/day of calcium over a 7-year period than in those who consumed more than 1,000 mg/day. The limitation of the study is that 40% of the teeth did not have detectable alveolar bone loss at baseline.
Eighty-five post-menopausal women received 400 IU per day of vitamin D and increased calcium intake to 1,000 mg per day. 83 Women were also randomized to receive either calcitriol or a placebo. After two years, 83% of the women either maintained or gained mandibular bone mass although no significant difference was attributable to calcitriol alone. The major limitations of this study are that 20% of the subjects were edentulous and data on periodontal disease status were not given. The results of this study are similar to those found in a more recent 3-year hormone replacement study in which 67 periodontally healthy post-menopausal women received only 1,000 mg of calcium and 400 IU of vitamin D per day (Fig. 6 ). 84 Over a 3-year period, there were significant increases in both alveolar bone mass and alveolar crest height (Fig. 6) . The apparent increase in crestal bone height was attributed to a reduction or complete refilling of the remodeling space. After 3 years, this increase in crestal density (decrease in crestal porosity) would have been most pronounced in subjects with vitamin D deficiency and radiographically would appear as an increase in alveolar crest height. The limitations of this study are that the women were periodontally healthy and there was no control arm for which women received only placebo.
LIMITATIONS OF STUDIES ON THE EFFECT OF VITAMIN D AND CALCIUM ON PERIODONTAL HEALTH
All of the above investigations had limitations. Most were observational. In some, dental measurements were secondary outcomes and in others procedures for randomization, masking, and data collection were not presented. Some studies lacked data on the cause of tooth loss and/or the periodontal-disease status of the patients. Often no data on exact amounts of supplementation were available. There was also a great deal of variation among the studies with regard to the amounts of supplementation and the monitoring of intakes. In many instances, supplementation/intakes were below recommended intakes and, therefore, may have been too small to produce effects, particularly for vitamin D, for which there is growing concern that current recommended intakes are too low. For the effects of vitamin D and calcium on periodontitis, there has never been a clinical trial in which randomization and blinding were carefully controlled, the periodontal disease status of patients known, periodontal disease measures were the primary outcomes, and levels of supplementation/intake optimized to produce maximal effects.
SUMMARY
As of 2002, there had been 70 randomized clinical trials of the effects of calcium and vitamin D on the postcranial skeleton, and 68 of these studies (97%) reported positive effects for supplementation. 58 Based upon a systematic review and meta-analysis of 15 of these trials (1,806 patients), it was determined that 2 or more years of supplementations resulted in 1.66% less bone loss at the lumbar spine and 1.64% less loss at the hip. 66 This may not seem to be a large benefit, but if this benefit were to be extended over decades or the lifetime of an individual, the benefit could be enormous, particularly in a patient with periodontal disease, which is generally considered to be a long-term, chronic condition. In a recent article in which osteoporotic, bonefragility fractures were discussed, it was pointed out that a rate of calcium depletion (bone loss) of 3%/year would have a measurable effect on bone strength; yet clinically the depletion would not be detectable for, at least, 10 years, and at lower (more typical) rates of loss, the clinical manifestation of the disease might take 30 years. 24 The long latency period of the disease does not, however, decrease its health importance.
Moreover, low levels of calcium intake and particularly vitamin D intake result in a low serum level of calcium that stimulates the parathyroid gland to produce PTH, which results in osteoclastogenesis. Periodontal disease results in the production of proinflammatory cytokines, which also result in osteoclastogenesis. It follows that alveolar bone in patients with periodontal disease and low levels of vitamin D and calcium should be under a heavier osteoclastic load than are bones such as the femur and spine. A number of infectious diseases have been linked with low levels of vitamin D, and it has been demonstrated that vitamin D can suppress cytokine production. 22 Because of periodontal disease's unique periodontal-pathogen, hard-tissue environment, it may be that the effect of vitamin D and calcium on alveolar bone is more pronounced than its effects in the spine and hip.
Bacteria are necessary but not sufficient for periodontal disease, which is multifactorial. The belief that all disease was caused by external invaders (bacteria or toxic) was a hurtle that nutritional scientists had to overcome, with the concept that people could become sick because of something lacking in their diets being inconceivable. 24 Numerous articles indicate that vitamin D and calcium deficiencies result in bone loss and increased inflammation, which are well recognized symptoms of periodontal disease. It has been suggested that calcium deficiency may be a risk factor for periodontal disease. 80 Perhaps vitamin D deficiency should also be considered as a risk factor in studies of the etiology of periodontal disease. Further research is needed to clearly define the health risks (including periodontal disease) associated with inadequate levels of vitamin D and calcium intake. 82, 85 
